Study of the coverage and the impact of the chemoprevention of seasonal malaria in Niger from 2013 to 2022: systematic review
Open Access
- 30 May 2025
- journal article
- review article
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 539
Abstract
Purpose Malaria remains a public health problem in Niger, especially among children under the age of five. To combat this scourge, since 2012, the World Health Organization (WHO) has recommended seasonal malaria chemoprevention (SMC), a strategy based on the administration of sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) during the period of high transmission. This systematic review assesses the coverage, efficacy, and challenges of SMC in Niger between 2013 and 2022, analyzing its impact on malaria morbidity and mortality. Materials and methods The PRISMA guidelines were used to ensure a rigorous and comprehensive recording of the systematic review process. Through searches in five different databases, articles were imported into Zotero software, then transferred to the Covidence application, where data processing was carried out. The selected articles were independently evaluated by two reviewers. These included studies that assessed coverage, malaria incidence, and the impact of SMC. Studies published in French and English were included. Data extraction from the included studies was performed, and a quality assessment was conducted, including an evaluation of the risk of bias. Results Among the six studies, three assessed SMC coverage in all eight regions of Niger while also evaluating side effects. They showed high overall coverage but low coverage in some areas. Another study examined the impact in terms of the incidence of complicated malaria, malaria-related hospitalization, and mortality. Another publication revealed that antibody responses against the blood and pre-erythrocytic stages of P. falciparum were higher in the area where SMC was implemented. Conclusions This study demonstrates that SMC has a significant impact on reducing malaria incidence. Although there is high overall coverage, variations exist, particularly in hard-to-reach areas. Few adverse events were reported. However, very few studies are available, highlighting the need for additional research in Niger to better understand this strategy.Keywords
This publication has 17 references indexed in Scilit:
- Effect of seasonal malaria chemoprevention on incidence of malaria among children under five years in Kotido and Moroto Districts, Uganda, 2021: time series analysisMalaria Journal, 2024
- Barriers to the quality delivery of seasonal malaria chemoprevention in Chad and Burkina Faso: a qualitative exploration of caregivers and community distributors’ perspectivesMalaria Journal, 2024
- Impact of seasonal malaria chemoprevention based on the number of medicines doses received on malaria burden among children aged 3–59 months in Nigeria: A propensity score‐matched analysisTropical Medicine & International Health, 2024
- Surveillance des effets indésirables lors des campagnes de la chimioprévention du paludisme saisonnier chez les enfants de 3-59 mois au Burkina FasoSanté Publique, 2023
- Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control StudyThe Journal of Infectious Diseases, 2023
- A non-randomised controlled trial to assess the protective effect of SMC in the context of high parasite resistance in UgandaResearch Square, 2022
- PRISMA 2020: a reporting guideline for the next generation of systematic reviewsJBI Evidence Synthesis, 2021
- Evidence that seasonal malaria chemoprevention with SPAQ influences blood and pre-erythrocytic stage antibody responses of Plasmodium falciparum infections in NigerMalaria Journal, 2021
- Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational studyThe Lancet, 2020
- Impact of seasonal malaria chemoprevention on hospital admissions and mortality in children under 5 years of age in Ouelessebougou, MaliMalaria Journal, 2020